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Purpose: Calcineurin inhibitors are used to prevent graft
versus host disease in allogeneic stem cell transplant re-
cipients. Achieving therapeutic drug levels prior to trans-
plant engraftment decreases the development of graft versus
host disease. The objective of this study is to investigate if
higher initial dosing of calcineurin inhibitors results in a
shorter time to therapeutic drug levels.
Methods: This study, approved by the Institutional Review
Board, is a retrospective chart review comparing two dosing
strategies of cyclosporine and tacrolimus. The following data
was collected: patient age, gender, ethnicity, initial dose of
cyclosporine or tacrolimus, time to therapeutic drug levels,
time to engraftment, change in bilirubin, and change in
serum creatinine. All data was recorded without patient
identiﬁers and maintained conﬁdentially. Data will be
divided into a low initial dosing group and a high initial
dosing group and time to therapeutic drug levels will be
compared. Descriptive statistics will be utilized to compare
starting doses of calcineurin inhibitors and time to thera-
peutic drug levels.
Conclusion: If correlation is shown, allogeneic stem cell
transplant recipients may be able to reach therapeutic drug
levels sooner and further prevent graft versus host disease
which would decrease mortality and morbidity in this high
risk population. Assessment of this dosing protocol may lead
to more aggressive and individualized dosing strategies.454
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High-dose cyclophosphamide (Cy) is a common component
of conditioning regimens that patients receive prior to he-
matopoietic cell transplant (HCT). Due to concerns for
increased risk of toxicity, obese patients at Virginia
Commonwealth University Health System (VCUHS) receive
doses of Cy based on an adjusted body weight (ABW; ABW ¼
[(total body weight [TBW] e ideal body weight [IBW]) x 0.4]
+ IBW) whereas non-obese patients receive doses based on
TBW. However, these practices are inconsistent with the
American Society of Clinical Oncology (ASCO) 2012 guide-
lines, which recommend that obese patients receive full-
dose chemotherapy. Interestingly, these guidelines excluded
patients with hematological malignancies undergoing HCT
from their literature review. Using a retrospective medical
record review, we examined whether there is a difference in
effectiveness and toxicity between obese and non-obese
patients who receive high-dose Cy prior to HCT.
The primary objective of this study was to determine if there
is a difference in toxicity between obese versus non-obese
patients during the ﬁrst 60 days following transplant.
Toxicity was measured as a composite endpoint of overall
toxicity, which was comprised of any grade 3 or 4 non-he-
matological toxicity, the incidence of pulmonary, hepatic,
renal, or cardiac toxicity, and each component individually.Secondary objectives were to compare the differences in
effectiveness between obese and non-obese patients
assessed by relapse at day +100, relapse at one year, death at
one year, chimerisms at days +30, +60, and +90, and the
incidence of acute graft versus host disease (aGVHD).We also
sought to evaluate the difference in time to engraftment and
rates of infection between groups. Chi-squared test and
Fisher’s exact test were used to assess the primary and sec-
ondary endpoints and two-sample t-tests were used to
assess time to engraftment.
Sixty-one patients met the inclusion criteria. Of these, 28
were considered to be obese while 33 were considered to be
non-obese. Mean BMI was 24.7  2.5 in non-obese patients
and 32.5  4.3 in obese patients. The mean Cy dose in non-
obese and obese patients was 56.80  10.4 mg/kg and 48.55
 3.3 mg/kg of TBW, respectively. The rate of overall toxicity
was greater in the obese patients compared to non-obese
patients (82% vs 52%, OR 4.3 [95% CI 1.3-14.1]), which was
driven by a signiﬁcantly greater incidence of renal dysfunc-
tion (79% vs 48%, OR 3.9 [95% CI 1.3-12.1]). There were no
differences in rates of grade 3 or 4 toxicity, hepatic
dysfunction, or any measure of effectiveness between
groups. Although obese patients are at increased risk of
toxicity, they appear to achieve the same effectiveness as
non-obese patients. Since the increased risk of toxicity is due
to increases in grade 2 renal toxicity, there is no evidence to
support changing the dosing practices at VCUHS.455
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High dose IV melphalan is widely used in preparative regi-
mens for hematopoietic cell transplantation. Package insert
recommendations state to prepare doses to a concentration
of </¼ 0.45 mg/mL in Normal Saline (NS) and to infuse
within 60 minutes of reconstitution. When using these rec-
ommendations, many doses must be prepared in volumes of
1000 mL or more which results in infusion rates of up to 2
liters/hour over 30 minutes. Available infusion pumps have
maximum infusion rate of 999 mL/hour, often requiring
doses be prepared in multiple bags and infused simulta-
neously using 2 pumps to ensure a 30 minute infusion time.
Melphalan was found to have 90% or greater stability at 60
and 90 minutes when diluted in NS polyoleﬁn bags to con-
centrations from 0.45 mg/mL to 2 mg/mL e personal
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This, in combination with available package insert data,
supports a wider range of options for preparation. In
December 2011 we implemented a simpler technique for
administration of melphalan by preparing all doses in a total
volume of 250 mL NS. This method yields concentrations
between 0.45 to 2 mg/mL for patients of a BSA from 0.81 to
3.56 m2 for 140 mg/m2 doses and 0.57 to 2.5 m2 for 200 mg/
m2 doses. In a review of the ﬁrst 30 autologous HCT patients
who received melphalan 200 mg/m2 via this method, me-
dian engraftment was on days 12 and 16 for neutrophils and
platelets, respectfully, which is the same as our historical
data for this transplant regimen. To date this method has
been used for over 350 transplant patients. This practice
change simpliﬁed both pharmacy and nursing procedures
such that all doses are dispensed in a single bag with a total
volume of 250 mL and infused via one infusion pump at a
standard rate of 500 mL/hour. This simpliﬁed compounding
and administration of doses decreases time spent by both
pharmacy and nursing for treatments using melphalan. The
use of a single bag and one standard infusion rate also re-
duces the likelihood of administration errors by eliminating
the need to calculate infusion rates and coordinate the use of
multiple pumps.456
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Background: Busulfan is an alkylating agent commonly used
for myeloablation in hematopoietic stem cell transplantation
(SCT). Narrow therapeutic index and 2-3 fold interpatient PK
variability underscores the need to further explore predictors
of busulfan clearance. This analysis aimed to predict the
percentage of patients who were within the targeted AUC
range of 4800 mM*minwith dosing strategies based on actual
body weight (ABW) or adjusted body weight (AdBW, and to
determine patient characteristics that may impact busulfan
clearance.
Methods: This retrospective analysis assessed allogeneic SCT
patients who received a test dose of 0.8 mg/kg IV busulfan,
dosed by AdBW, prior to conditioning therapy containing
therapeutically dosed busulfan. All patients were treated
between June 2004 and July 2013 at the University of North
Carolina at Chapel Hill. Noncompartmental PK parameters
were calculated from this test dose using Phoenix
WinNonlinPharsight software. Measured PK data were
obtained from test the test dose and used to extrapolate an
AUC for ABWand AdBW. Acceptable AUCs werewithin 15% of
the targeted of 4800 mM*min.
A linear model with log of busulfan test dose clearance as
an outcome and patient characteristics that included disease
state, bone marrow donor type, gender, race, ethnicity, body
surface area (BSA), anticonvulsant prophylaxis used (leve-
tiracetam or phenytoin), total bilirubin and serum creatinine
was ﬁt.
Results: The study reviewed a total of 102 patients with a
mean age of 40.3 (range 18 to 63). The analysis included 63males, 87 Caucasians, and 5 African Americans. Seizure
prophylaxis with levetiracetamwas given to 41 patients, and
51 patients received phenytoin. Based extrapolated PK data,
42% of patients dosed by ABW were within targeted AUC
range, versus 47% of patients dosed by AdBW.
After adjusting for patient characteristics, a unit increase
in BSA was associated with 0.68 (p ¼ < 0.001) increase in
busulfan log(clearance). Although not statistically signiﬁcant,
African American race was associated with a trend towards
decreased clearance (p ¼ 0.064). No correlation was seen for
age (p ¼ 0.226), gender (p ¼ 0.417337), or for any other
variable that was assessed.
Discussion: Weight-based busulfan dosing using AdBW or
ABW each results in <50% of patients being achieving a goal
AUC of 4800 mM*min. Interpatient variability of IV busulfan
may be partially explained by BSA, yet differences in race,
gender, and age did not correlate busulfan clearance. These
data suggest that other dosing strategies, such as PK-guided
dosing, may help to minimize over/under dosing and to
overcome interpatient variability.457
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Background: Allogeneic hematopoietic cell transplant (HCT)
is increasingly used to treat patients with malignancies. The
use of pre-HCT immunosuppressive conditioning chemo-
therapy and post-HCT immunosuppression predispose these
patients to infections. A departmental vaccination guideline
was implemented in Singapore General Hospital (SGH) in
year 2004. As a clinical improvement initiative to facilitate
easy reference and prompt prescribing, the guideline was
updated and modiﬁed into a vaccination chart detailing the
vaccines needed at various time-points in October 2012. This
chart was ﬁled in the patients’ progress notes to ensure ac-
curate tracking of patients’ vaccination status. The aim of this
study was to review the usefulness of this chart in facilitating
prompt prescribing.
